Benefit from Beta Interferon in the Treatment of Multiple Sclerosis (CROSBI ID 127437)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Bošnjak-Pašić, Marija ; Lisak, Marijana ; Uremović, Melita ; Vidrih, Branka, Demarin, Vida
engleski
Benefit from Beta Interferon in the Treatment of Multiple Sclerosis
Over the past twelve years, beta interferons la and lb have been inereasingly used as immunomodulatory agents in the treatment of multiple sclerosis as well as for prophylaxis of disease progression. In Croatia, the cost of beta interferons 1a and lb has been covered by the Croatian Institute of Health Insurance since 1997. Despite numerous doubts about their real benefit, having in mind their price, side effects and occurrence of neutralizing antibodies, numerous clinical trials have confirmed their efficacy The most efficient arc interferon beta la (Rebif© in a dose of 12 MIU, subcutaneously, three times per week), interferon beta 16 (Betaferon® in a dose of 8 MIU, subcutaneously, every other day) and interferon beta-la (Avonex® in a dose of 6 MIU weekly intramuscularly).
Multiple sclerosis - drug therapy; Interferons - adverse effects; Treatment outcome; Clinical trials
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano